Beam Therapeutics Inc. (BEAM) Stock Analysis

Q: What is the BEAM stock price target?

Take-profit $46.08 (+49.8% upside). Prior stop was $28.62.

Q: What are the risks of investing in BEAM?

Concentration risk — Pipeline: risto-cel sickle cell BLA; Quality below floor (1.8 < 4.0); Quality below floor (1.8 < 4.0); EARNINGS_PROXIMITY:5d<=7d.

Q: Is BEAM overvalued or undervalued?

Beam Therapeutics Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 5.4/10. Overall verdict: Sell.

Q: What do analysts say about BEAM?

25 analysts cover BEAM with a consensus score of 4.3/5. Average price target: $51.

Breakout setup

SellVALUE-TRAP 1/5Moderate ConfidenceUpdated 2026-04-30

Healthcare · Biotechnology

Earnings in 5 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $30.77: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 34%; Below-average business quality.

Beam Therapeutics is a pre-commercial biotech developing base-editing genetic medicines. Lead programs are risto-cel (autologous HSC for sickle cell disease, BLA targeted year-end 2026) and BEAM-302 (in vivo LNP for alpha-1 antitrypsin deficiency in Phase 1/2). No products are... Read more

$30.77+49.8% A.UpsideScore 4.6/10#126 of 158 Biotechnology

Stop $28.62Target $46.08(analyst − 10%)A.R:R 3.3:1

Analyst target$51.20+66.4%15 analysts

$46.08our TP

$30.77price

$51.20mean

$80

Passes 6/7 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 5d<=7d. Suitability: aggressive.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Pipeline: risto-cel sickle cell BLA

Quality below floor (1.8 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-6.7

Mkt Cap$3.0B

EV/EBITDA-5.1

Profit Mgn-57.2%

ROE-8.1%

Rev Growth279.5%

Beta2.19

DividendNone

Rating analysts25

Quality Signals

Piotroski F4/9

Options Flow

P/C0.40bullish

IV85%elevated

Max Pain$44+43.0% vs spot

Concentration Risks(10-K Item 1A)

HIGHpipelineristo-cel sickle cell BLA
10-K Item 1: 'We expect to submit a BLA for risto-cel as early as year-end 2026'

Material Events(8-K, last 90d)

2026-03-05Item 1.02MEDIUM
On March 2, 2026, Beam and Bio Palette Co. mutually terminated their base editing License Agreement due to Bio Palette's planned dissolution. A standby license from Kobe University simultaneously activated, preserving Beam's rights under the same scope.
SEC filing →
2026-02-05Item 5.02LOW
Carole Ho resigned from Beam Board effective February 27, 2026. No disagreement with Company on any matter relating to operations, policies or practices. No successor named for board seat.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value5.415%0.81

Quality1.815%0.27

Growth5.015%0.75

Momentum6.210%0.62

Sentiment7.010%0.70

Insider Activity3.310%0.33

Peer Rank4.010%0.40

Technical Setup4.05%0.20

Risk Profile3.75%0.19

Catalyst6.35%0.32

Overall (Σ contributions)4.58

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static

Roe

0.0

Roa

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

4.4

Current Ratio

5.0

Moat

5.0

Cash-burning: FCF -158% of revenueNo competitive moatQuality concerns

GatesEARNINGS PROXIMITY 5d<=7dMomentum 6.2>=5.5A.R:R 3.3 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARBreakoutSuitability: Aggressive

RSI

60 · Neutral

↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $23.44Resistance $32.48

Price Targets

$29

$46

A.Upside+49.8%

A.R:R3.3:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.8 < 4.0)

! EARNINGS_PROXIMITY:5d<=7d

Earnings

2/4 beats

Next Earnings2026-05-05 (5d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is BEAM stock a buy right now?

Sell if holding. Engine safety override at $30.77: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 3.3:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 34%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $28.62. Score 4.6/10, moderate confidence.

What is the BEAM stock price target?

Take-profit target: $46.08 (+49.8% upside). Prior stop was $28.62. Stop-loss: $28.62.

What are the risks of investing in BEAM?

Concentration risk — Pipeline: risto-cel sickle cell BLA; Quality below floor (1.8 < 4.0).

Is BEAM overvalued or undervalued?

Beam Therapeutics Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 5.4/10. Verdict: Sell.

What do analysts say about BEAM?

25 analysts cover BEAM with a consensus score of 4.3/5. Average price target: $51.

What does Beam Therapeutics Inc. do?Beam Therapeutics is a pre-commercial biotech developing base-editing genetic medicines. Lead programs are risto-cel...